Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults
Equal first author contributors
- 10.2991/chi.d.200115.001How to use a DOI?
- GvHD prevention; Calcineurin inhibitors; mTOR inhibitors; Post-transplant cyclophosphamide
Graft-versus-host disease (GvHD) in its acute and chronic forms continues to represent a significant barrier to the success and wide-applicability of blood and marrow transplantation as a potentially curative treatment modality for a number of benign and malignant blood conditions. Presently, calcineurin inhibitor (CNI)-based regimens remain the most commonly used prevention strategy, although post-transplant cyclophosphamide is emerging as an alternative approach, and is providing a backbone for innovative CNI-free combinations. In this paper, we review the current strategies used for the prevention of GvHD, and highlight some of the developing and promising combinations.
- © 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Download article (PDF)
View full text (HTML)
Cite this article
TY - JOUR AU - Cosmin Tegla AU - Jun Choi AU - Maher Abdul-Hay AU - Frank Cirrone AU - Kelli Cole AU - A Samer Al-Homsi PY - 2020 DA - 2020/01/28 TI - Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults JO - Clinical Hematology International SP - 5 EP - 12 VL - 2 IS - 1 SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.200115.001 DO - 10.2991/chi.d.200115.001 ID - Tegla2020 ER -